Galectin Therapeutic (GALT) Stock Price, Quote & News

Company Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and dev...

Industry: Biotechnology

Sector: Healthcare

Phone: 678 620 3186

Website: galectintherapeutics.com

Address:

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, United States

JBRUN Aug. 19 at 12:43 PM

$GALT 3 shares @ $3.05 try harder moron shorts

2 · Reply

Indibviduate1 Aug. 19 at 10:32 AM

$GALT $GALT imho the smart thing to do would be to lock in a sale or partnership with lots of cvr to cover phase 3 trial design approval and more so that the macro economic environment doesn’t rob us of a short squeeze or a partner or buyer once funding costs go up a lot or after ai or pvt credit fails.

0 · Reply

Indibviduate1 Aug. 19 at 8:19 AM

$GALT Well I hope they make a deal for partnership or buyout as soon as possible because the world economic situation is looking dark and money is going to become much more expensive to borrow.

2 · Reply

SamGantVHee Aug. 19 at 4:13 AM

$GALT rising wedge pattern playing out, generally considered a bearish indicator. If no news, need to break above $3.70(wedge lines meet this Friday)... if not $2.80's may be in play(not expecting this, but it is possible). Short volume was 77% of yesterday's daily volume, but only 47% of today's daily volume. Both days we saw significantly more buying than selling, including large block orders. 250,000 shares available to borrow. Shorts may be covering? If so price isn't budging much, which is discouraging. RSI is at 50, which I like. Nice and neutral for a big bounce off of good news.

0 · Reply

Indibviduate1 Aug. 19 at 3:01 AM

$GALT based on public information? If there are ndas then the public information isn’t representative of what’s going on behind the scenes. Head fake percentages. Results based on no real information

2 · Reply

Indibviduate1 Aug. 19 at 2:41 AM

$GALT I don’t understand why shorts bother to sell it down at the start of the day to just watch the quiet accumulators buying it back once it reaches lows Nothing achieved and lots of borrowed shares wasted. But I guess there’s nothing else shorts can do to avoid margin calls.

1 · Reply

ThomasLD Aug. 19 at 1:54 AM

$GALT From AI: Based strictly on the public information available as of August 18, 2026: ~60% — active negotiations, no definitive partner yet ~30% — advanced/near-final partnership discussions that cannot yet be disclosed ~10% — genuinely shifting toward a Galectin-alone Phase 3 The Q3 protocol submission itself is therefore not a partnership catalyst. It’s a regulatory catalyst. The potentially much bigger catalyst would be: Phase 3 protocol + financing/partner announcement And if Galectin were to announce a major pharma partner around the same time, I would regard that as a very different valuation event from simply filing the protocol.

1 · Reply

ThomasLD Aug. 18 at 11:01 PM

$GALT

0 · Reply

BigBenBroke Aug. 18 at 8:38 PM

$GALT Added today !

0 · Reply

ThomasLD Aug. 18 at 8:12 PM

$GALT Good luck 🍀 everyone! Thx you Kilarck!

0 · Reply

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

Aug 14, 2026, 7:00 AM EDT - 5 days ago

Galectin Therapeutics Quarterly report: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 5 days ago

Galectin Therapeutics Earnings release: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 15 days ago

Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

2026-06-23T12:38:18.000Z - 2 months ago

Galectin Therapeutics reaches alignment with FDA on belapectin pathway

Jun 23, 2026, 8:00 AM EDT - 2 months ago

Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension

2026-05-27T15:47:04.000Z - 2 months ago

Galectin Therapeutics presents belapectin data at EASL 2026

May 27, 2026, 8:00 AM EDT - 3 months ago

Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis

May 15, 2026, 8:00 AM EDT - 3 months ago

Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update

May 15, 2026, 7:00 AM EDT - 3 months ago

Galectin Therapeutics Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

Galectin Therapeutics Earnings release: Q1 2026

2026-05-11T20:22:35.000Z - 3 months ago

Galectin Therapeutics publishes NAVIGATE Phase 2b trial results

May 11, 2026, 8:00 AM EDT - 3 months ago

Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology

Apr 27, 2026, 9:00 AM EDT - 4 months ago

Galectin Therapeutics, Inc. Investigated by the Portnoy Law Firm

2026-03-31T20:17:36.000Z - 5 months ago

Galectin Therapeutics files $200M mixed securities shelf

Mar 31, 2026, 8:00 AM EDT - 5 months ago

Galectin Therapeutics Registration statement: Registration filing

Mar 31, 2026, 7:00 AM EDT - 5 months ago

Galectin Therapeutics Earnings release: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 5 months ago

Galectin Therapeutics Annual report: Q4 2025

2026-03-17T12:15:29.000Z - 5 months ago

Galectin Therapeutics appoints Henry Brem to board of directors

Mar 10, 2026, 12:00 PM EDT - 5 months ago

Galectin Therapeutics Transcript: KOL event

2025-12-19T13:11:22.000Z - 8 months ago

Galectin Therapeutics provides regulatory update following FDA written response

2025-12-17T11:11:31.000Z - 8 months ago

Galectin Therapeutics price target raised to $11 from $6 at H.C. Wainwright

Dec 5, 2025, 6:00 AM EST - 9 months ago

Galectin Therapeutics Slides: Corporate presentation

Dec 3, 2025, 11:00 AM EST - 9 months ago

Galectin Therapeutics Transcript: AGM 2025

2025-11-14T13:10:43.000Z - 9 months ago

Galectin Therapeutics reports Q4 EPS (13c) vs (18c) last year

Nov 14, 2025, 8:00 AM EST - 9 months ago

Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update

Nov 14, 2025, 8:00 AM EST - 9 months ago

Galectin Therapeutics Earnings release: Q3 2025

Nov 14, 2025, 8:00 AM EST - 9 months ago

Galectin Therapeutics Quarterly report: Q3 2025

2025-11-10T13:32:14.000Z - 10 months ago

Galectin Therapeutics presents NAVIGATE trial results at AASLD

Oct 22, 2025, 8:00 AM EDT - 10 months ago

Galectin Therapeutics Proxy statement: Proxy Filing

Oct 22, 2025, 8:00 AM EDT - 10 months ago

Galectin Therapeutics Proxy statement: Proxy Filing

Oct 21, 2025, 7:00 AM EDT - 10 months ago

Galectin Therapeutics Transcript: H.C. Wainwright Liver Disease Virtual Conference

Sep 8, 2025, 1:00 PM EDT - 1 year ago

Galectin Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 7, 2025, 6:00 PM EDT - 1 year ago

Galectin Therapeutics Slides: Corporate Presentation

Sep 2, 2025, 8:00 AM EDT - 1 year ago

Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-14T12:11:00.000Z - 1 year ago

Galectin Therapeutics reports Q2 EPS (12c) vs (20c) last year

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Quarterly report: Q2 2025

2025-07-09T12:21:20.000Z - 1 year ago

Galectin Therapeutics announces $10M credt line from Richard Uihlein

2025-06-17T10:05:08.000Z - 1 year ago

Galectin Therapeutics assumed with a Buy at H.C. Wainwright

Jun 16, 2025, 12:00 PM EDT - 1 year ago

Galectin Therapeutics Transcript: Study Result

Jun 16, 2025, 12:00 PM EDT - 1 year ago

Galectin Therapeutics Press release: Study Result

Jun 16, 2025, 12:00 PM EDT - 1 year ago

Galectin Therapeutics Slides: Study Result

May 15, 2025, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Earnings release: Q1 2025

May 15, 2025, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Quarterly report: Q1 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Annual report: Q4 2024

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Earnings release: Q4 2024

Jan 10, 2025, 8:00 AM EST - 1 year ago

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

Dec 20, 2024, 8:00 AM EST - 1 year ago

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

Dec 3, 2024, 7:00 AM EST - 1 year ago

Galectin Therapeutics Proxy statement: Proxy Filing

Dec 3, 2024, 7:00 AM EST - 1 year ago

Galectin Therapeutics Proxy statement: Proxy Filing

Nov 18, 2024, 8:00 AM EST - 1 year ago

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Nov 14, 2024, 8:00 AM EST - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

Nov 14, 2024, 7:30 AM EST - 1 year ago

Galectin Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 7:30 AM EST - 1 year ago

Galectin Therapeutics Quarterly report: Q3 2024

Oct 15, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Oct 7, 2024, 10:00 AM EDT - 2 years ago

Galectin Therapeutics Transcript: 9th Annual MASH Investor Conference

Sep 9, 2024, 12:00 PM EDT - 2 years ago

Galectin Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 3, 2024, 8:30 AM EDT - 2 years ago

Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Earnings release: Q2 2024

Aug 1, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer

Jun 4, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress

May 15, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

May 15, 2024, 7:00 AM EDT - 2 years ago

Galectin Therapeutics Quarterly report: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

Galectin Therapeutics Earnings release: Q1 2024

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Earnings release: Q4 2023

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Annual report: Q4 2023

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

Dec 7, 2023, 6:00 AM EST - 2 years ago

PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023

Nov 13, 2023, 8:45 AM EST - 3 years ago

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Nov 13, 2023, 8:00 AM EST - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Nov 13, 2023, 7:00 AM EST - 3 years ago

Galectin Therapeutics Quarterly report: Q3 2023

Nov 13, 2023, 7:00 AM EST - 3 years ago

Galectin Therapeutics Earnings release: Q3 2023

Nov 3, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

Oct 23, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023

Oct 12, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors

Oct 6, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Proxy statement: Proxy Filing

Oct 6, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Proxy statement: Proxy Filing

Sep 26, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023

Sep 13, 2023, 5:22 PM EDT - 3 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023

Sep 7, 2023, 12:00 PM EDT - 3 years ago

Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023

Aug 14, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Galectin Therapeutics Quarterly report: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Galectin Therapeutics Earnings release: Q2 2023

May 15, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update

May 15, 2023, 7:00 AM EDT - 3 years ago

Galectin Therapeutics Quarterly report: Q1 2023

May 15, 2023, 7:00 AM EDT - 3 years ago

Galectin Therapeutics Earnings release: Q1 2023

Apr 27, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023

Apr 18, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics' Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases

Apr 14, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Registration statement: Registration Filing

Mar 30, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update

Mar 30, 2023, 7:00 AM EDT - 3 years ago

Galectin Therapeutics Earnings release: Q4 2022

Mar 30, 2023, 7:00 AM EDT - 3 years ago

Galectin Therapeutics Annual report: Q4 2022

Mar 16, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Jan 24, 2023, 8:00 AM EST - 3 years ago

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

Jan 5, 2023, 8:00 AM EST - 3 years ago

Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Nov 28, 2022, 8:00 AM EST - 4 years ago

Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit

Nov 14, 2022, 8:00 AM EST - 4 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update

Nov 14, 2022, 7:00 AM EST - 4 years ago

Galectin Therapeutics Quarterly report: Q3 2022

Nov 14, 2022, 7:00 AM EST - 4 years ago

Galectin Therapeutics Earnings release: Q3 2022

Nov 1, 2022, 8:00 AM EDT - 4 years ago

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD

JBRUN Aug. 19 at 12:43 PM

$GALT 3 shares @ $3.05 try harder moron shorts

2 · Reply

Indibviduate1 Aug. 19 at 10:32 AM

0 · Reply

Indibviduate1 Aug. 19 at 8:19 AM

$GALT Well I hope they make a deal for partnership or buyout as soon as possible because the world economic situation is looking dark and money is going to become much more expensive to borrow.

2 · Reply

SamGantVHee Aug. 19 at 4:13 AM

0 · Reply

Indibviduate1 Aug. 19 at 3:01 AM

2 · Reply

Indibviduate1 Aug. 19 at 2:41 AM

1 · Reply

ThomasLD Aug. 19 at 1:54 AM

1 · Reply

ThomasLD Aug. 18 at 11:01 PM

$GALT

0 · Reply

BigBenBroke Aug. 18 at 8:38 PM

$GALT Added today !

0 · Reply

ThomasLD Aug. 18 at 8:12 PM

$GALT Good luck 🍀 everyone! Thx you Kilarck!

0 · Reply

History101 Aug. 18 at 7:50 PM

$GALT added

0 · Reply

History101 Aug. 18 at 7:43 PM

$GALT wow!! look at that late day run!! we were down 4% so i went to focus on other stocks and now i'm back on GALT!! awesome

0 · Reply

DuvalFish Aug. 18 at 7:34 PM

$GALT come on buyout. Give me a couple billion buyout and some cvrs. Guessing where the sp goes with a partnership will be so difficult.

2 · Reply

swardfishtrader Aug. 18 at 7:32 PM

$GALT 🚀 textbook perfect.

1 · Reply

Scarlivertriumphant Aug. 18 at 7:01 PM

$GALT Our time is coming.

1 · Reply

AshleySchaeffer_BMW Aug. 18 at 6:37 PM

$GALT with peak sales like ours bo can hit 5 bil easily, partner news takes us to 3 bil most likely fully diluted we will do well here lads!

1 · Reply

Bobear12 Aug. 18 at 5:12 PM

$GALT Each share of Galectin Therapeutics (GALT) would be worth approximately $29.75 to $45.55, depending on whether you calculate the value using basic or fully diluted outstanding shares.

2 · Reply

JollyAcorn2021 Aug. 18 at 4:59 PM

$GALT One day, hopefully and should be SOON, we will all log on to ST a see that a PR dropped titled something like "XYZ Large Cap Bio and Galectin Therapeutics Enter Strategic Collaboration for the Development and Commercialization of Belapectin" with an after hours gap up $7 and a days worth of trading that see us squeeze to around $20.

3 · Reply

Indibviduate1 Aug. 18 at 4:21 PM

$GALT similar pattern every day now. They let the shorts sell it down with borrowed shares then they quietly accumulate as it comes back up again.

0 · Reply

Kilarck Aug. 18 at 4:18 PM

$GALT Long and strong. Patience pays!!!

2 · Reply

PJP62 Aug. 18 at 4:01 PM

$GALT Company could get 3 billion easily if sold.

3 · Reply

Indibviduate1 Aug. 18 at 3:40 PM

$GALT yup. Slow quiet accumulation without moving the price

0 · Reply

Market Cap	231.16M
Revenue (ttm)	0.00
Net Income (ttm)	-30.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	317,900
Avg Vol	741,026
Day's Range	N/A - N/A
Shares Out	65.86M
Stochastic %K	77%
Beta	0.41
Analysts	Sell
Price Target	$11.00